In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genome editing company CRISPR Therapeutics nets $52mm in IPO

Executive Summary

CRISPR Therapeutics AG (genome editing focused on CRISPR/Cas9-based therapeutics) netted $52mm in its initial public offering of 4mm shares at $14 (down-sized and below the anticipated price range) on the Nasdaq. Concurrently, the company raised $35mm through the sale of 2.5mm shares to development partner Bayer through a private placement offering.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies